FY2025 Earnings Forecast for CLDX Issued By Leerink Partnrs

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2025 earnings estimates for shares of Celldex Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical company will post earnings per share of ($3.26) for the year, down from their previous forecast of ($3.22). The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics' FY2026 earnings at ($4.45) EPS and FY2027 earnings at ($4.20) EPS.

A number of other analysts have also weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $62.25.

Celldex Therapeutics Stock Performance

Shares of NASDAQ:CLDX traded up $0.14 on Friday, hitting $21.67. The company's stock had a trading volume of 272,855 shares, compared to its average volume of 1,007,429. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -8.43 and a beta of 1.60. The stock's 50-day moving average is $25.02 and its two-hundred day moving average is $30.24. Celldex Therapeutics has a 12 month low of $20.98 and a 12 month high of $53.18.

Hedge Funds Weigh In On Celldex Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its position in Celldex Therapeutics by 23.7% during the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock valued at $291,000 after buying an additional 1,504 shares during the period. SG Americas Securities LLC lifted its holdings in Celldex Therapeutics by 124.6% in the 3rd quarter. SG Americas Securities LLC now owns 20,316 shares of the biopharmaceutical company's stock worth $691,000 after purchasing an additional 11,272 shares during the last quarter. Handelsbanken Fonder AB grew its holdings in Celldex Therapeutics by 23.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company's stock valued at $469,000 after buying an additional 2,600 shares during the last quarter. Creative Planning acquired a new position in shares of Celldex Therapeutics during the third quarter worth approximately $504,000. Finally, Values First Advisors Inc. boosted its position in shares of Celldex Therapeutics by 13.4% in the third quarter. Values First Advisors Inc. now owns 24,172 shares of the biopharmaceutical company's stock valued at $822,000 after acquiring an additional 2,853 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.